Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.64 |
| ▸ | TSHR | P16473 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.62 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4415967 | 0.92 | CDK5 (0.67) | HPGDALDH1A1TSHRLMNAHTT | |
| SCHEMBL4419719 | 0.91 | ALDH1A1 (0.64) | HPGDALDH1A1TSHRLMNAHTT | |
| SCHEMBL4421888 | 0.90 | ALDH1A1 (0.63) | HPGDALDH1A1TSHRLMNAHTT | |
| SCHEMBL4423432 | 0.90 | ALDH1A1 (0.63) | HPGDALDH1A1TSHRLMNAHTT | |
| SCHEMBL4419057 | 0.90 | ALDH1A1 (0.73) | HPGDALDH1A1TSHRLMNAHTT | |
| SCHEMBL4425009 | 0.88 | ALDH1A1 (0.60) | HPGDALDH1A1TSHRLMNAHTT | |
| SCHEMBL4425302 | 0.85 | HPGD (0.73) | HPGDALDH1A1TSHRLMNAHTT | |
| SCHEMBL4419755 | 0.83 | HPGD (0.73) | HPGDALDH1A1TSHRLMNAHTT | |
| SCHEMBL4413960 | 0.80 | HPGD (0.65) | HPGDALDH1A1CDK5CDK5R1 | |
| SCHEMBL4428098 | 0.79 | ALDH1A1 (0.65) | HPGDALDH1A1TSHRLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | GRM5, GRIK5, GRM1 | HPGD 2657/4885ALDH1A1 3104/4885TSHR 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.